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The concentration of free cytosolic Ca2 and the voltage
across the plasma membrane are major determinants of cell
function. Ca2-permeable non-selective cationic channels are
known to regulate these parameters, but understanding of these
channels remains inadequate. Herewe focus on transient recep-
tor potential canonical 4 and 5 proteins (TRPC4 and TRPC5),
which assemble as homomers or heteromerize with TRPC1 to
form Ca2-permeable non-selective cationic channels in many
mammalian cell types. Multiple roles have been suggested,
including in epilepsy, innate fear, pain, and cardiac remodeling,
but limitations in tools to probe these channels have restricted
progress. A key question is whether we can overcome these lim-
itations and develop tools that are high-quality, reliable, easy to
use, and readily accessible for all investigators. Here, through
chemical synthesis and studies of native and overexpressed
channels by Ca2 and patch-clamp assays, we describe compound
31, a remarkable small-molecule inhibitorofTRPC1/4/5 channels.
Its potency ranged from 9 to 1300 pM, depending on the TRPC1/
4/5 subtype and activationmechanism.Other channel types inves-
tigated were unaffected, including TRPC3, TRPC6, TRPV1,
TRPV4, TRPA1, TRPM2, TRPM8, and store-operated Ca2 entry
mediated by Orai1. These findings suggest identification of an
important experimental tool compound, which has much higher
potency for inhibiting TRPC1/4/5 channels than previously
reported agents, impressive specificity, and graded subtype selec-
tivitywithintheTRPC1/4/5channel family.Thecompoundshould
greatly facilitate future studies of these ion channels. We suggest
naming this TRPC1/4/5-inhibitory compound Pico145.
Transient receptor potential canonical (TRPC)4 proteins
assemble asmultimers around a central ion pore to enableCa2
and Na entry intomammalian cells (1, 2). Themultimers may
be repeats of the same TRPC protein (homomers) or mixtures
of differentTRPCproteins (heteromers). A group ofTRPCpro-
teins that are thought to cluster together consists of TRPC1,
TRPC4, and TRPC5 (TRPC1/4/5). TRPC1 was first reported in
1995, and since then it has been found to be broadly expressed
(1–3). Among theTRPCproteins, it is unusual in failing to form
ion channels or forming thempoorlywhenoverexpressed alone
in cell lines (2, 4–6). Overexpressed TRPC1, by contrast, read-
ily forms functional heteromers with TRPC4 and TRPC5 (5, 7,
8). TRPC4 and TRPC5 are also capable of forming functional
homomers without TRPC1, but these might be relatively
uncommon in physiology because TRPC1 is so widely ex-
pressed. The specific functions andmechanisms of the TRPC1/
4/5 channels and the relative importance of homomers and
heteromers remain poorly understood. One of the many chal-
lenges has been to determine their relevance in store-operated
Ca2 entry, a type of Ca2 entry seen in most cell types when
the intracellular Ca2 stores are depleted (9).
A key restriction on TRPC1/4/5 studies has been the lack of
pharmacological tools with which to specifically activate or
inhibit the channels (10). An important recent breakthrough
was the discovery of ()-englerin A (EA), a highly efficacious,
potent, and apparently specific activator of TRPC1/4/5 chan-
nels (homomers and heteromers) (8, 11, 12). For investigations
of the physiological significance and translational potential of
the channels, however, there is a pressing need for potent and
specific inhibitors. Probably, the most characterized inhibitor
reported so far is the TRPC4/5 inhibitor ML204 (13). It inhib-
ited TRPC4 with an IC50 of about 1 M and caused about 65%
inhibition of TRPC5 at 10 M (13). This is not particularly
potent, and, as we show in the current study, there is a weaker
effect on TRPC1-containing channels.
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Despite the limitations of the TRPC1/4/5 tools, there is com-
pelling evidence for important roles of the channels, notably in
animal models of human pathophysiology and clinical samples.
The channels are suggested to have roles in epilepsy, innate
fear, pain, rheumatoid arthritis, and adverse cardiac remodel-
ing, for example (10, 14–21). TRPC4 and TRPC5 knock-out
mice exhibited reduced innate fear and reduced anxiety (16,
17). TRPC5 has been implicated in the regulation of adiponec-
tin secretion (22), kidney barrier function (23), and barorecep-
tor control of blood pressure (24). TRPC4 knock-out mice and
mice treated withML204 showed less body licking and abdom-
inal retractions in response to mustard oil (18). TRPC4 and
TRPC5 contributed to maintenance of pain hypersensitivity
and neuropathy (25). TRPC1 was up-regulated and had a posi-
tive role in neointimal hyperplasia of the human saphenous
vein, where it may function in partnership with TRPC5 (4, 26).
In vascular smooth muscle cells from the human saphenous
vein, TRPC5-dependent channels were activated by sphingo-
sine 1-phosphate, and this drove cell migration. Other studies
point to roles in aspects of cancer: drug resistance and its trans-
mission via extracellular vesicles, tumor vascularization, and
cancer cell death evoked by EA (27).
Compound 31 (C31) was specified in an international patent
application, where it was suggested to be a pharmacologically
effective inhibitor of TRPC5 channels (28). We initially synthe-
sized this compound to independently confirm its effectiveness as
Figure 1. C31 inhibits TRPC5 and TRPC4 homomeric channels. A, example Ca2measurement data from a single 96-well plate showing concentration-de-
pendent inhibition of EA (10 nM)-evoked Ca2 entry by 0.03, 0.3, 1, 10, and 30 nM C31 in HEK 293 Tet cells expressing human TRPC5 (N 4/data point). B,
summary data for experiments of the type shown in A plotted as a percentage of the response to EA in the vehicle control for C31 (n  6 independent
experiments). The fitted curve is the Hill equation with IC50 1.32 nM (n/N 6/24). C, example Ca
2measurement data from a single 96-well plate showing
concentration-dependent inhibition of EA (10 nM)-evoked Ca2 entry by 0.01, 0.1, 0.3, 1, 3, and 10 nM C31 in HEK 293 Tet cells expressing human TRPC4 (N
4/data point). D, summary data for experiments of the type shown in C plotted as a percentage of the response to EA in the vehicle control for C31 (n  6
independent experiments). The fitted curve is the Hill equation with IC50  0.349 nM (n/N  6/24). E, example whole-cell patch-clamp data from a TRPC4-
expressing HEK 293 cell showing current sampled at90 and90mV during ramp changes in voltages. EA and C31were bath-applied at the concentrations
indicated (C31, 0.01, 0.03, 0.1, 0.3, and 1 nM). F, example IVs from the experiment in E. The numbers to the left specify C31 concentrations in nM.EA, indicates
current sampled before EA was applied. Error bars, S.D.
TRPC1/4/5 inhibitor
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a TRPC5 inhibitor.We found that it is an inhibitor of TRPC5 and
soprogressed todeterminingwhether it has effectsonothermem-
bers of this protein family. We found remarkable effects, particu-
larly on TRPC4 and importantly also its heteromer with TRPC1.
Results
The chemical structure of C31 is shown in supplemental Fig.
S1. C31 was synthesized according to three different synthetic
routes, all providing analytically pure material according to
NMR and LC-MS analysis (see supplemental Figs. S2–S4 and
Schemes S1–S3).
C31 is a nanomolar inhibitor of TRPC5
To observe the functional effects of C31 on TRPC5, we used
humanembryonic kidney (HEK)293 cells containing stably incor-
porated tetracycline-inducible expression of exogenous human
TRPC5.The cells were in 96-well plates and loadedwith the intra-
cellular Ca2 indicator fura-2 to detect Ca2 entry via activated
TRPC5 channels. Application of 10 nM EA caused robust activa-
tion of the channels (Fig. 1A), similar to previous observations (8).
Cells preincubated and maintained in the presence of 30 nM C31
failed to show responses to EA (Fig. 1A). Investigation of other
concentrations of C31 revealed the concentration for 50% inhibi-
tion (IC50) to be 1.3 nM (Fig. 1,A andB). The data suggest thatC31
was a nanomolar inhibitor of EA-activated TRPC5 channels.
C31 ismore potent against TRPC4
Wenext investigatedTRPC4 using a similar approach to that
for TRPC5. EA is also an agonist at TRPC4 channels with a con-
centration for 50% effect (EC50) similar to that seen with TRPC5
(11.2 nM; cf. 7.6 nM) (8). It was therefore used again at 10 nM to
stimulate thechannels.C31 inhibitedTRPC4,but in this case, 3nM
C31was sufficient for complete inhibition, and the IC50 was 0.349
nM (Fig. 1,C andD).Thedata suggest thatC31 inhibitedTRPC4as
well as TRPC5 and that it was more potent against TRPC4.
C31may act directly to inhibit the channels
Because the interpretation of Ca2measurement data can be
complicated by indirect effects on cellular Ca2 handling and
membrane potential, we further investigated the effect of C31
by patch recording. First we used whole-cell recording, in
which current through TRPC4 channels wasmeasured across a
range of voltages. C31 strongly and concentration-dependently
inhibited the TRPC4-mediated ionic current, and its effect was
at least partially reversible on washout (Fig. 1E). The ionic cur-
rent showed the characteristic seatlike current-voltage rela-
Figure 2. C31 inhibits TRPC4 channel currents in outside-out patches. A, example outside-out patch-clamp data from a TRPC4-expressing HEK 293 cell
showing current sampled at100 and100mV during ramp changes in voltages. EA and C31were bath-applied at the concentrations indicated. B, example
IVs from the experiment inAduring the second application of EA. The EA response before C31 is shown in red and afterwashout of C31 in pink. Before and after
washout of EA are indicated by EA. C, example outside-out patch-clamp data from a TRPC4-expressing HEK 293 cell displaying IVs during the first application
of EAas shown inA. The EA responsebeforeC31 is shown in red andafterwashout of C31 inpink. Current before EA is indicatedbyEA.D,mean concentration-
response data for experiments for the type shown in A, B, and C. The numbers of independent experiments are indicated in parentheses. Error bars, S.D.
Figure 3. TRPC5 homomer and TRPC5-TRPC1 concatemer have distinct
IVs. Typical whole-cell IVs are shown for TRPC5 expressed alone (A) and the
TRPC5-TRPC1 concatemer before (EA, black) and after bath application of
100nMEA (red) (B). The IVsweregeneratedusing voltage ramps from100 to
100 mV delivered every 10 s.
TRPC1/4/5 inhibitor
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tionship (IV) of TRPC4 channels, and the inhibitionwas similar
at negative and positive voltages (Fig. 1F). Second, we used
excised outside-out membrane patch recording in which the
patchwas detached from the cell, and its ionic environmentwas
strongly controlled. We used 100 nM EA to maximize the size
and clarity of the ionic current against which the effect of C31
could be tested (Fig. 2A). C31 inhibited the TRPC4-mediated
ionic current in a concentration-dependentmanner, and its effect
was reversible onwashout (Fig. 2,A–D).Thedata suggest thatC31
inhibited the channels independently of cellular constituents,
other Ca2-handling mechanisms, or membrane potential. The
data are suggestive of C31 acting directly on the channels.
Figure 4. C31 inhibits heteromeric channels. A, example Ca2measurement data from a single 96-well plate showing concentration-dependent inhibition
of EA (10 nM)-evoked Ca2 entry by 1, 30, 100, and 1000 M ML204 in HEK 293 Tet cells expressing human TRPC4-TRPC1 concatemer (N 4/data point). B,
summary data for experiments of the type shown in A plotted as a percentage of the response to EA in the vehicle control for ML204 (n  6 independent
experiments). The fitted curve is the Hill equation with IC50  58 M (n/N  6/24). C, example Ca
2 measurement data from a single 96-well plate showing
concentration-dependent inhibition of EA (10 nM)-evoked Ca2 entry by 0.01, 0.03, 0.1, 0.3, 1, and 3 nM C31 in HEK 293 Tet cells expressing human TRPC5-
TRPC1 concatemer (N 3/data point). D, summary data for experiments of the type shown in C plotted as a percentage of the response to EA in the vehicle
control for C31 (n 8 independent experiments). The fitted curve is the Hill equation with IC50 0.2 nM (n/N 8/24). E and F, similar to C andD but using HEK
293Tet cells expressing thehumanTRPC4-TRPC1concatemer and resulting in aHill equationwith IC500.033nM (n/N6/24).G, examplewhole-cell current
recording from aHEK 293 Tet cell expressing the TRPC4-TRPC1 concatemer showing current sampled at90 and90mV during ramp changes in voltages.
Bath-applied as indicatedwere 30 nM EA and 0.01, 0.03, 0.1, 0.3, and 1 nM C31.H, example IVs for the experiment inG.Numbers to the left indicate the addition
of C31 with concentrations in nM. Error bars, S.D.
TRPC1/4/5 inhibitor
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Heteromers of TRPC1with TRPC4/5 are pharmacologically
distinct
Because of the importance of heteromers containing TRPC1,
we generated concatemers of TRPC4 with TRPC1 and TRPC5
with TRPC1, stably incorporating them in HEK 293 cells for
tetracycline-inducible expression. The concatemers formed
functional channels with fingerprint single-curve IVs, which
contrastedwith the seatlike IVs of TRPC4 andTRPC5 (e.g. Figs.
1F and 3 (A and B)). The pharmacology of the concatemers was
first investigated using a fura-2 Ca2 indicator. The signals
were small relative to those of homomers because TRPC1 sup-
presses Ca2 permeability (6). ML204, the previously reported
lowmicromolar inhibitor of TRPC4,was active against TRPC4-
TRPC1 concatemer only at relatively high concentrations
(IC50  58 M) (Fig. 4, A and B). The data suggest relative
resistance of TRPC4-TRPC1 heteromer to ML204.
Heteromers with TRPC1 are potently inhibited by C31
In contrast to ML204, C31 was potent against Ca2 entry
through heteromers (Fig. 4, C–F). As little as 3 nM C31 was
sufficient to prevent Ca2 entry through TRPC5-TRPC1 (IC50
0.199 nM) (Fig. 4, C and D). Even less C31 (0.3 nM) abolished
Ca2 entry through TRPC4-TRPC1 (IC50 0.033 nM) (Fig. 4, E
and F). TRPC4-TRPC1 channels were also investigated by
whole-cell patch-clamp recording, where C31 caused potent
concentration-dependent inhibition, and its effect was largely
reversible on washout (Fig. 4, G and H). The data suggest that
C31 is a potent inhibitor of Ca2 entry through heteromers.
Potency of C31 is reduced by elevated EA concentration
EA and C31 are chemically distinct, but both are clearly
potent modulators of the channels, so we considered the possi-
bility of an interaction between their effects. We used whole-
cellpatch-clamprecordingtocomparetheconcentrationdepen-
dence of C31 blockade in the presence of 10 and 100 nM EA.
Example data for TRPC4-TRPC1 are shown (Fig. 5, A–C). C31
(0.3 nM) caused almost complete blockade in 10 nM EA but only
partial blockade in 100 nM EA (Fig. 5, A–C). The recovery from
C31blockadewas lessgood in10nMEAcomparedwith100nMEA
(Fig. 5A), the explanation for which was unclear. The data suggest
that EA reduced the potency of C31 at TRPC4-TRPC1 channels.
Concentration-response curves were constructed for C31 in
thepresenceof10, 30, and100nMEAforTRPC4-TRPC1channels
and in the presence of 10 and 100nMEA forTRPC4 channels (Fig.
5, D and E). The effects were measured at90 and90 mV. At
90 mV, the potency of C31 was similar for 10 and 30 nM EA
Figure 5. EA negatively modulates C31 potency. A, example whole-cell patch-clamp data from a TRPC4-TRPC1-expressing HEK 293 cell showing current
sampled at90 and90mV during ramp changes in voltages. EA and C31 were bath-applied at the concentrations indicated. B and C, example IVs from the
experiment in A for 10 nM EA (B) and 100 nM EA (C) applications. C31 was in addition to the EA. D and E, mean concentration-response data for current
amplitudes sampled at 90 mV (D) and 90 mV (E) during ramp changes in voltages in TRPC4-TRPC1 (C4-C1, black symbols) or TRPC4 (C4, red symbols)-
expressing HEK 293 cells studied at the indicated EA concentrations. The numbers of independent experiments are indicated in parentheses. The fitted curves
are Hill equations that indicated IC50 values as follows.D, for TRPC4-TRPC1, the IC50 values were 0.068 nM (10 nM EA), 0.061 nM (30 nM EA), and 0.481 nM (100 nM
EA); for TRPC4, the IC50 valueswere 0.063 nM (10 nM EA) and 0.593 nM (100 nM EA). E, for TRPC4-TRPC1, the IC50 valueswere 0.042 nM (10 nM EA), 0.078 nM (30 nM
EA), and 0.441 nM (100 nM EA); for TRPC4, the IC50 values were 0.169 nM (10 nM EA) and 0.916 nM (100 nM EA). Error bars, S.D.
TRPC1/4/5 inhibitor
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acting at TRPC4-TRPC1 channels and 10 nMEA acting at TRPC4
channels (Fig. 5D). Butwhen 100nMEAactivatedTRPC4-TRPC1
orTRPC4 channels, the potency ofC31was substantially less (Fig.
5D). At 90 mV, the potency of C31 was best for 10 nM EA at
TRPC4-TRPC1channels and less good for30nMEA(Fig. 5E).The
potencywas less for 10 nMEAatTRPC4 channels (Fig. 5E). Again,
when 100 nM EA activated TRPC4-TRPC1 or TRPC4 channels,
the potency of C31 was less good (Fig. 5E).
The data suggest that the potency ofC31was regulated by EA
concentration, becoming less with increased EA concentration.
The data also suggest mild voltage dependence in the potency
of C31 and reinforce the concept of graded subtype specificity.
C31 potently inhibits channels activated by sphingosine
1-phosphate (S1P)
The impact of EA concentration led us to ask whether the
action of C31 required EA as the agonist. We therefore acti-
vated channels instead with S1P, a physiological substance that
acts via a G protein signaling pathway (4, 29).We again focused
on TRPC4 and TRPC4-TRPC1 channels. The S1P responses
tended to be smaller and less robust than EA responses, espe-
cially for TRPC4-TRPC1 channels (Fig. 6, A–D). C31 was a
potent and concentration-dependent inhibitor of both channel
types (Fig. 6, A–D). S1P-activated TRPC4 and TRPC4-TRPC1
channels showed similar sensitivities to C31. For TRPC4 chan-
nels, the IC50 values at 100 and 100 mV were estimated to
be 0.012 and 0.030 nM, respectively (Fig. 6E). For TRPC4-
TRPC1 channels, the IC50 values at 100 and 100 mV were
estimated to be 0.009 and 0.059 nM, respectively (Fig. 6F).
In studies of TRPC4-TRPC1 channels, we observed basal
current before application of S1P and observed that C31 some-
times caused the current amplitude to decrease below the pre-
S1P amplitude (Fig. 6, C–F). We suspected that the basal cur-
rent reflected constitutive activity of TRPC4-TRPC1 channels
or activity relating to endogenous (background) channels. In
the absence of S1P, C31 had no effect on basal ionic current
Figure 6. C31 inhibits channels activated by a physiological agonist. A, example whole-cell patch-clamp data from a TRPC4-expressing HEK 293 cell
showing current sampled at100 and100 mV during ramp changes in voltages. S1P, C31, and EA were bath-applied at the concentrations indicated. B,
example IVs from the experiment in A in the absence (S1P) and presence of S1P plus C31 at the indicated concentrations (e.g.0.01 represents 0.01 nM C31).
C andD, as forA and Bbut for a TRPC4-TRPC1-expressingHEK 293 cell. E and F, mean concentration-response data for current amplitudes sampled at100mV
(red) and 100 mV (black) during ramp changes in voltages in TRPC4 (E)- and TRPC4-TRPC1 (F)-expressing HEK 293 cells studied as illustrated in A–D. The
numbers of independent experiments are indicated inparentheses. The fitted curves areHill equations that suggested approximate IC50 values as follows: 0.012
nM (100 mV) and 0.030 nM (100 mV) (E); 0.009 nM (100 mV) and 0.059 nM (100 mV) (F). Error bars, S.D.
TRPC1/4/5 inhibitor
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in TRPC4-expressing cells and no effect or a small inhibitory
effect on basal current in TRPC4-TRPC1-expressing cells
(Fig. 7).
S1P-evoked Ca2 entry through TRPC4-TRPC1 channels
was also potently inhibited by C31 (IC50 0.011 nM) (Fig. 8, A
and B). S1P-evoked TRPC5-mediated Ca2 entry was also
inhibited by C31 (Fig. 8C).
The data suggest that the action of C31 did not depend on EA
and that it had potent effects against channel activity evoked by
the physiological agonist, S1P.
C31 hasmore complex effects on channels activated by
gadolinium ion (Gd3)
TRPC4 and TRPC5 channels are also stimulated by ions,
such as Gd3, and these effects might reflect a role of the chan-
nels in detecting toxic metal ions (30, 31). The stimulatory
effect was not as robust as that of EA, but TRPC4-mediated
currents were detected in response to Gd3 (Fig. 9). Unexpect-
edly, low concentrations of C31 were agonistic in the presence
of Gd3, although higher concentrations were inhibitory (Fig.
9, A–E). Gd3 did not activate TRPC4-TRPC1 channels (n 
4). C31 (100 nM) was tested against TRPC5-mediated Ca2
entry and was inhibitory (Fig. 9F). The data suggest that Gd3
enabled an agonist effect of low concentrations of C31 but that
higher concentrations of C31 were inhibitory.
C31 has specificity for TRPC1/4/5 channels
Based on sequence analysis and functional studies, the clos-
est type of TRP channel to TRPC1/4/5 is mediated by the
TRPC3/6/7 cluster of proteins. To investigate C31 against
members of these subfamilies, we stably incorporated TRPC3
in HEK 293 cells for tetracycline-inducible expression (Fig.
10A). These channels were not activated by EA but could be
activated by the diacylglycerol analogue 1-oleoyl-2-acetyl-sn-
Figure 7. C31 has little or no effect in the absence of exogenous channel agonists. A, examplewhole-cell patch-clamp data from a TRPC4-expressing HEK
293 cell showing current sampled at100 and100 mV during ramp changes in voltage. C31 and EA were bath-applied at the concentrations indicated. B,
example whole-cell patch-clamp data from a TRPC4-TRPC1-expressing HEK 293 cell showing current sampled at100 and100mV during ramp changes in
voltages. C31andEAwerebath-appliedat the concentrations indicated.AandB, C31wasappliedat 0.01, 0.03, 0.1, 0.3, and1nM.CandD,meanabsolute current
amplitude data for the types of experiment illustrated in A and B (n 3 each). Error bars, S.D.
TRPC1/4/5 inhibitor
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glycerol (OAG), as reported previously (32) (Fig. 10A). 100 nM
C31 had no effect on TRPC3-mediated Ca2 entry (Fig. 10A).
Likewise, 100 nM had no effect on OAG-evoked (500 M) Ca2
entry into transient transfected HEK 293 cells expressing
human TRPC6 (Fig. 10B). Another subclass of TRP channels is
the V class. For this class, we investigated TRPV1 and TRPV4
and again found no effect of 100 nM C31 (Fig. 10, C andD). We
investigated another class of transient receptor potential chan-
nels that is activated by H2O2, TRPM2 channels (33), also
expressed using the tetracycline-inducible system in HEK 293
cells (Fig. 10E). 100 nM C31 had no effect on TRPM2-mediated
Ca2 entry (Fig. 10E). Similarly, 100 nM C31 had no effect on
another M class subfamily (TRPM8; Fig. 10F). To further
explore the selectivity of C31, we tested it against TRPA1 and
once more found no effect (Fig. 10G). The data suggest speci-
ficity of C31 for TRPC1/4/5 channels.
Endogenous channels are sensitive to C31
All of the above data were generated against overexpressed
channels. We therefore investigated whether C31 affected
endogenous channels, many of whichmay be heteromeric with
TRPC1. Previous studies have suggested that A498 renal cell
carcinoma cells contain endogenous EA-activated TRPC1/
TRPC4 heteromeric channels (8). To determine the sensitivity
of these channels to C31, we measured intracellular Ca2 ele-
vations in response to EA (Fig. 11A). C31 (0.3 nM) was sufficient
to abolish the Ca2 entry (IC50 0.048 nM) (Fig. 11, A and B).
Another EA-sensitive cancer cell line (Hs578T cells) was stud-
ied, and it was also sensitive to C31 (IC50 0.11 nM) (Fig. 11, C
and D). The data suggest that endogenous EA-activated chan-
nels were inhibited by C31.
C31 lacks effect on store-operated Ca2 entry
Controversial in the Ca2 channel field has been the role of
TRPC1/4/5 channels in store-operated Ca2 entry, which is
Ca2 entry occurring on adding extracellular Ca2 back to cells
that have been store-depleted in Ca2-free medium with the
endoplasmic reticulum Ca2-ATPase inhibitor, thapsigargin
(9). Therefore, we tested C31 against store-operated Ca2
entry. First, we did this using A498 cells because these cells
contained endogenous TRPC1/TRPC4 channels, which were
potently inhibited by C31 (Fig. 11, A and B). There was a large
store-operated Ca2 entry into A498 cells, which was strongly
inhibited by RO2959 (2,6-difluoro-N-5-[4-methyl-1-(5-meth-
yl-thiazol-2-yl)-1,2,5,6-tetrahydro-pyridin-3-yl]-pyrazin-2-yl-
benzamide hydrochloride), a known inhibitor of this type of
Ca2 entry (Fig. 12,A andB) (34). Strikingly, 100 nMC31hadno
effect on the Ca2 entry (Fig. 12,A and B).We also investigated
the endogenous store-operated Ca2 entry of wild-type HEK
293 cells and human umbilical vein endothelial cells (HUVECs)
(Fig. 12,C–F). These signals were also inhibited by RO2959 but
not C31 (Fig. 12,C–F). The data suggest that TRPC1/4/5 chan-
nels did not contribute to store-operated Ca2 entry into A498
cells, HEK 293 cells, or HUVECs.
Figure 8. C31 inhibits Ca2 entry evoked by S1P. A, example Ca2 measurement data from a single 96-well plate showing concentration-dependent
inhibition of S1P (200 nM)-evoked Ca2 entry by 1, 10, and 300 pM C31 in HEK 293 Tet cells expressing TRPC4-TRPC1 channels (N 4/data point). B, summary
data for experiments of the type shown in A plotted as a percentage of the response to S1P in the vehicle control for C31. The fitted curve is the Hill equation
with IC50 11.2 pM.C, example Ca
2measurement data froma single 96-well plate showing inhibition of S1P (5M)-evokedCa2 entry by 100nMC31 inHEK 293
Tet cells expressing TRPC5 channels (N 4/data point). TheCa2 entry evokedby S1Pwas abolishedby 100nMC31 in all experiments (n/N 6/24 each). Error
bars, S.D.
TRPC1/4/5 inhibitor
J. Biol. Chem. (2017) 292(20) 8158–8173 8165
 at U
N
IV
ERSITY
 O
F LEED
S on June 26, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
C31 lacks effect on histamine-evoked Ca2 elevation in
endothelial cells
Store-operated Ca2 entry evoked by the thapsigargin Ca2
addback protocol may not be the same as Ca2 entry caused by
a physiological agonist. We therefore investigated the effect of
histamineonHUVECs in the continuouspresenceof extracellular
Ca2 (Figs. 13 and 14). Histamine (0.3–100 M) caused a fast rise
in intracellularCa2,which thendeclined toaplateau (Figs. 13and
14).The initial rise is thought to reflectCa2 release from intracel-
lular stores, whichmay cause at least partial depletion of intracel-
lular Ca2 stores. C31 had no effect, whereas RO2959 strongly
suppressed the plateau but not the initial rise (Figs. 13 and 14).
When the response to 0.3Mhistaminewas studied over a longer
period, a second phase of Ca2 elevation was observed (Fig. 13, E
and F). This signal was also not inhibited byC31 and even showed
a tendency to be potentiated (Fig. 13, E and F). The data suggest
that TRPC1/4/5 channels did not contribute positively to hista-
mine-evoked Ca2 release or entry into HUVECs.
Discussion
The data suggest superb effectiveness, potency, and specific-
ity of C31 as an inhibitor of channels formed by TRPC1/4/5
proteins. Importantly, C31 inhibited heteromeric channels
involving TRPC1 and had graded potency and differential char-
acteristics against channels formed by different combinations
of TRPC1/4/5 (Table 1).
It has been challenging to find selective and potent pharma-
cological agents for the modulation of TRPC1/4/5 channels
Figure 9. Potentiation and inhibition of channel activity in the presence of Gd3. A, example whole-cell patch-clamp data from a TRPC4-expressing HEK
293 cell showing current sampled at100 and100mV during ramp changes in voltages. Gd3 and C31 were bath-applied at the concentrations indicated
(C31, 0.01, 0.03, 0.1, 0.3, and 1 nM). B, example IVs from the experiment in A in the absence (Gd3) and presence of Gd3 plus C31 at the indicated
concentrations (e.g.0.01 represents 0.01 nM C31). C, example whole-cell patch-clamp data from a TRPC4-expressing HEK 293 cell showing current sampled
at100 and100mV during ramp changes in voltages. Gd3 and C31 were bath-applied at the concentrations indicated (C31, 0.01, 0.03, 0.1, 0.3, and 1 nM).
D, for the first applicationofGd3 shown inC, example IVs in the absence (Gd3) andpresenceofGd3plus 0.01nMC31. E, for the secondapplicationofGd3
shown in C, example IVs in the absence (Gd3) and presence of Gd3 plus C31 at the indicated concentrations (e.g.0.01 represents 0.01 nM C31). A–E, the
examples shown were selected as exemplary from four independent recordings. F, example Ca2 measurement data from a single 96-well plate showing
inhibition of Gd3 (100M)-evoked Ca2 entry by 100 nM C31 in HEK 293 Tet cells expressing TRPC5 channels (N 4/data point). The Ca2 entry evoked by
S1P was abolished by 100 nM C31 in all experiments (n/N 6/24 each). Error bars, S.D.
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(10). Small-molecule inhibitors, such as SKF-93635 and 2-APB,
are nonspecific. ML204 and the anti-histamine clemizole
hydrochloride were more recently identified and are more spe-
cific, but they only inhibit the channels at micromolar concen-
trations (13, 35).We show here that the IC50 forML204 against
the TRPC4-TRPC1 heteromeric channel is 58 M. There are
also other less potent compounds compared with ML204,
namely M084-derived compounds, which inhibit TRPC4/
TRPC5 channels (36). Galangin is a natural product recently
identified as an inhibitor of TRPC4/5 channels, butmicromolar
concentrations were needed, the compound was not specific,
and the effect against TRPC1-containing channels was weak
(37). Small-molecule activators of TRPC1/4/5 channels have
been identified and include riluzole and rosiglitazone, but they
are nonspecific, and high concentrations are needed for an
effect (38, 39). EA was the first identified remarkable small-
molecule modulator of TRPC1/4/5 channels (8, 11). It is an
agonist with nanomolar potency, good specificity, and strong
efficacy. C31 is an inhibitor that is also remarkable, perhaps
more so than EA. It is even more potent than EA and also
appears to be highly specific. Importantly, it had better effect on
TRPC1-containing heteromers, and therewas subtype specific-
ity over 2 orders of magnitude concentration range, all in the
picomolar to low-nanomolar range. Because of the remarkable
and unprecedented potency of C31 as a TRPC1/4/5 inhibitor,
we validated its effect using three different batches of C31,
made using three independent synthetic routes (see supple-
mental Information). All three batches were analytically pure
according to NMR and LC-MS analysis (supplemental Infor-
mation and Figs. S5–S7) and displayed the same activity against
TRPC4-TRPC1 concatemers (supplemental Information and
Fig. S8), validating C31 as the active compound.
The detailed mechanism of action of C31 remains to be elu-
cidated. We do not have evidence that C31 directly binds the
channels, but our data suggest a direct effect via the extracellu-
lar surface of the channels or extracellular leaflet of the bilayer.
The effect of C31 was not as rapid as might be expected for an
agent that plugs the ion pore. Voltage dependence in the action
ofC31was relativelymild, also not supporting the idea of block-
ade deep in the ion pore and electric field. Moreover, an ago-
Figure 10. C31 has no effect on seven other types of Ca2-permeable channels. A and B, example Ca2measurement data from a single 96-well plate
showing no effect of 100 nM C31 on OAG (50 and 500M)-evoked Ca2 entry into HEK 293 Tet cells expressing human TRPC3 (N 6/data point, n/N 6/36)
and TRPC6 (transient transfectedHEK 293,N 3/data point,n/N 4/12), respectively.C, example Ca2measurement data froma single 96-well plate showing
no effect of 100 nM C31 on capsaicin (Cap; 10 M)-evoked Ca2 entry and full inhibition by capsazepine (CZP; 1 M), in transient transfected HEK 293 cells
expressing human TRPV1 (N 3/data point, n/N 4/12).D, example Ca2measurement data from a single 96-well plate showing no effect of 100 nM C31 on
4-phorbol-12,13-didecanoate (4PDD; 5 M)-evoked Ca2 entry into CHO cells stably expressing human TRPV4 (N 3/data point, n/N 6/18). E, example
Ca2measurement data froma single 96-well plate showing no effect of 100 nMC31 onhydrogenperoxide (H2O2; 1mM)-evokedCa
2 entry intoHEK 293 Tet
cells expressing human TRPM2 (N 6/data point, n/N 6/36). F, example Ca2measurement data froma single 96-well plate showing no effect of 100 nMC31
on menthol (Men; 100 M)-evoked Ca2 entry into transient transfected HEK 293 cells expressing human TRPM8 (N  3/data point, n/N  4/12) and full
inhibition by M8-B hydrochloride (300 nM). G, example Ca2measurement data from a single 96-well plate showing no effect of 100 nM C31 on allyl isothio-
cyanate (AITC; 30M)-evoked Ca2 entry into transiently transfected HEK 293 cells expressing human TRPA1 (N 3/data point, n/N 5/15) and full inhibition
by A967079 (A96; 5 M). Error bars, S.D.
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nistic effect of C31 was observed in the presence of Gd3, sug-
gesting that C31 might be a modulator. Intriguingly, C31 had
no agonist effect in the absence of Gd3, indicating that Gd3
exposed a different mode of action of C31 or an effect that
depended on the prior gating state. The effect of C31 was not
dependent on EA, yet it was modulated by EA. There is no firm
evidence that EA directly binds the channels, but it is effective
in outside-out patches, so it apparently acts directly (8). Be-
cause of the differences in the chemistry of EA and C31, we
suggest that it is likely that elevated EA concentration reduces
the inhibitory potency of C31 via allostericmodulation (i.e. that
EA and C31 bind different sites).
C31wasmore potent against TRPC4-mediated ionic current
than TRPC4-mediated Ca2 entry: IC50 0.063–0.169 nM ver-
sus 0.349 nM (activation by 10 nM EA) (Table 1). This difference
was not evident for TRPC4-TRPC1 channels: IC50  0.068–
0.042 nM versus 0.033 nM (activation by 10 nMEA) (Table 1).We
speculate that the differential effect was caused by technical
differences in the electrophysiology and Ca2 measurement
experiments combined with differences in the effects of C31 on
TRPC4 and TRPC4-TRPC1 channels. Voltage dependence was
most obvious in the potency of C31 against TRPC4, and the
membrane potential was not voltage-clamped in theCa2mea-
surement studies. However, this explanation is not quantita-
tively sufficient to explain the difference, so it might be that the
potency of C31 against TRPC4 depends on additional unknown
factors.
C31 was more potent than we expected against endogenous
EA-evoked Ca2 entry into A498 cells. We used 100 nM EA in
these experiments to ensure a robust Ca2 response. In patch-
clamp recordings, this concentration of EA reduced the IC50 for
C31 against TRPC4-TRPC1 channels to about 0.45 nM,whereas
in A498 cells, the IC50 for C31 against Ca2 entry was about 10
times lower (Table 1). There are various possible explanations,
including that theTRPC4-TRPC1 concatemer did not perfectly
mimic the endogenous channels of A498 cells and that channel
density affected potency.
The first publications on TRPC1/4/5 suggested roles in Ca2
entry triggered by Ca2 store depletion (i.e. that these proteins
were subunits of store-operated Ca2 channels, capacitative
Ca2 entry, or Ca2 release-activated Ca2 (CRAC) channels)
(40–42). Ever since, debate has continued about whether they
do indeed serve this role. A challenge came with the discovery
of the Orai1 protein, a previously unrecognized type of Ca2
channel subunit that could reliably reproduce the properties of
CRAC channels if co-expressed with STIM1 protein (9, 43).
Depletion of Orai1 by short interfering RNA suppressed store-
operated Ca2 entry in the hands of many investigators.
Whereas depletion of TRPC1/4/5 (especially TRPC1) has also
suppressed store-operated Ca2 entry, some investigators have
not been able to observe this effect in their cells and experimen-
tal conditions. Prominent publications have suggested interac-
tions between STIM1 and the TRPC1/4/5 proteins (44, 45).
There seems now to be broad agreement that TRPC1/4/5 pro-
teins do not contribute to CRAC channels, but the topics of
other less Ca2-selective channels activated by store depletion
and the phenomenon of Ca2 entry in store-depleted cells are
broader, and there is less clarity about the roles of TRPC1/4/5.
Figure 11. C31 inhibits endogenous channels in A498 and Hs578T cancer cells. A, example Ca2 measurement data from a 96-well plate showing
inhibition of EA (100 nM)-evoked Ca2 entry by 0.01, 0.03, 0.1, 0.3, 1, and 3 nM C31 in A498 cells (N 4/data point). B, summary data for experiments of the type
shown in A as a percentage of the response to EA in the vehicle control for C31 (n 6 independent experiments). The fitted curve is the Hill equation with
IC50  0.048 nM (n/N  6/24). C, example Ca
2 measurement data from a single 96-well plate showing concentration-dependent inhibition of EA (100
nM)-evokedCa2 entry by 0.01, 0.03, 0.1, 0.3, 1, and 3nMC31 inHs578T cells (N 4/data point).D, summary data for experiments of the type shown inCplotted
as a percentage of the response to EA in the vehicle control for C31 (n 5 independent experiments). The fitted curve is the Hill equation with IC50 0.11 nM
(n/N 5/20). Error bars, S.D.
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We suggest that C31 could be a useful tool for investigating
these roles in many cell and tissue types and experimental con-
ditions, all of which might have a bearing on whether TRPC1/
4/5 proteins contribute. We investigated C31 against store-op-
erated Ca2 entry in three cell types as examples. Strikingly, in
all cases, C31 had no effect on the store-operated Ca2 entry at
a concentration orders of magnitude greater than that needed
to inhibit TRPC1/4/5 channels. We suggest that these data
exclude the contribution of TRPC1/4/5 channels to store-op-
erated Ca2 entry in these cells under these conditions. There
should be caution, however, because store depletion causes
clustering of membrane proteins and potentially new assem-
blies of proteins that are not otherwise present; if these new
assemblies involve TRPC1/4/5 proteins forming Ca2-perme-
ation pathways with other proteins, these assemblies might
then not be sensitive to C31.
In conclusion, the study suggests C31 as a promising tool for
critical evaluation of TRPC1/4/5 channels in biological mech-
anisms and that store-operated Ca2 entry can occur in a cell
without any contribution from TRPC1/4/5 channels although
functional channels exist in the same cell. Because of the special
effects of C31, we suggest the name Pico145.
Materials andmethods
Cell culture
HEK 293 cells stably expressing tetracycline-regulated
human TRPC3, TRPC4, TRPC5, or TRPM2 have been de-
scribed (8, 33, 37, 46). All cells were grown at 37 °C in a 5% CO2
incubator and culture media supplemented with fetal bovine
serum (FBS; 10%), penicillin (50 units/ml), and streptomycin
(0.5mg/ml) (Sigma-Aldrich). ThemodifiedHEK 293 cells were
Figure12. C31 lacks effect on store-operatedCa2entry.A, exampleCa2measurement data froma96-well plate showing effects of 100nMC31 and10M
RO2959 on Ca2 elevation upon adding back extracellular 1.5 mM Ca2 after depletion of intracellular stores with thapsigargin (TG; 1 M) in A498 cells (n 6
for each data point). B, summary data for experiments of the same type (A) plotted as a percentage of themaximum Ca2 add-back response (n/N 6/24). C,
exampleCa2measurementdata froma single 96-well plate showing theeffects of 100nMC31and10MRO2959on intracellular Ca2elevation that occurred
upon adding back extracellular 1.5 mM Ca2 after depletion of intracellular Ca2 stores with thapsigargin (TG; 1 M) in HEK 293 cells (N  6/data point). D,
summary data forC (n/N 6/24). E, as forCbut in HUVECs. F, summary data for experiments of the same type (E) plotted as a percentage of themaximumCa2
add-back response (n/N 5/25). Error bars, S.D. ***, p 0.001; NS, not significant.
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maintained in Dulbecco’s modified Eagle’s medium/F-12 Glu-
taMAX supplemented with selection antibiotics blasticidin (5
g/ml) and Zeocin (400g/ml) (Invitrogen). To induce expres-
sion of channels in these modified HEK 293 cells, 1 g/ml tet-
racycline was added to the media 24 h before experiments.
A498 cells and Hs578T cells were maintained in minimum
Eagle’s medium with Earle’s balanced salt solution, L-gluta-
mine, 2.2 g/liter NaHCO3 (PAN-Biotech, Aidenbach, Ger-
many) and in RPMI 1640 GlutaMAX (Invitrogen), respectively.
HUVECs were cultured in EGM-2 growth medium supple-
mented with an EGM-2 bullet kit (Lonza). TRPV4 was studied
in Chinese hamster ovary (CHO) K1 cells stably expressing
human TRPV4 and maintained in Ham’s F-12 (Gibco) in the
presence of 1 mg/ml G418 (Sigma).
Transfected HEK 293 cells
Transfections of HEK 293 cells with human TRPC6, TRPA1,
TRPV1, andTRPM8 (vector; pcDNA3.1)were performed using
FuGENE HD transfection reagent (Roche Applied Science).
The HEK 293 cells were split and plated, 5 105 cells/well, in a
6-well culture dish 24 h before transfection in 2 ml of DMEM/
F-12 GlutaMAXmedium. Next the cells were transfected using
a ratio of 3:1 ml of FuGENE HD/g of total cDNA (stock (1
g/l). The transfection reaction was done in a 1.5-ml micro-
centrifuge tube for each well, and the following materials were
added to the reaction: 100l of Opti-MEM (Gibco; 37 °C), 1g
of human cDNA, and finally 3 l of the FuGENE HD transfec-
tion reagent. Transfection reactions were mixed vigorously by
vortexing and incubated at room temperature for 15 min.
Finally, the reactions were added to each well, and the 6-well
plate was incubated at 37 °C in a 5% CO2. The next day, the
transfected cultured cells were removed to 96-well clear-bot-
tom poly-D-lysine-coated black plates (Corning Life Sciences,
Lowell, MA) and incubated, additionally, overnight for the
Ca2 measurement.
Generation of TRPC4-TRPC1 and TRPC5-TRPC1 concatemers
Human TRPC4 and TRPC1 were cloned upstream and
downstream, respectively, of a four-amino acid linker (ASAS),
flanked by AgeI and SacII restriction endonuclease sites, that
had previously been introduced into pcDNATM 4/TO (8).
TRPC4 , including an N-terminal Kozak sequence, was
inserted between BamHI and AgeI restriction sites using
hTRPC4 /pcDNATM 4/TO (8), a PCR template (forward
primer, 5-AGTCGGATCCGCCACCATGGCTCAGTTCTA-
TTACAAAAG-3; reverse primer, 5-AGTTACCGGTCAAT-
CTTGTGGTCACGTAATCTTC-3). TRPC1 was inserted
between SacII and XbaI restriction sites using hTRPC1/pIRES
Figure 13. C31 lacks effect on histamine-evoked Ca2 entry into endothelial cells. A, example Ca2measurement data from a 96-well plate showing the
effects of 100 nM C31 and 10M RO2959 on Ca2 elevation in response to 30M histamine in the continuous presence of extracellular 1.5mM Ca2 in HUVECs
(N 6/data point). Summary data for experiments of the same type (A)measured 300 s (B) after the start of histamine application and on the peak (C) response
(n/N 4/16).D, as forAbut using 0.3Mhistamine and showingonly summary data (n/N 3/12). E, example Ca2data froma96-well plate showing the effect
of 100 nM C31 on Ca2 elevation during a 22.5-min response to 0.3 M histamine in the presence of extracellular 1.5 mM Ca2 in HUVECs (n 6 for each data
point). F, summary data for experiments of the same type (E) measured 740 s after the start of histamine application and plotted as a percentage of the
maximum Ca2 add-back response (n/N 6/36). Error bars, S.D. *, p 0.05; ***, p 0.001; NS, not significant.
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as a PCR template (forward primer, 5-ACTCCGCGGCATG-
ATGGCGGCCCTG-3; reverse primer, 5-AGTCTCTAGAT-
TAATTTCTTGGATAAAACATAGCATATTTAG-3). HEK
293 cells stably expressing the TRPC5-TRPC1 and TRPC4-
TRPC1 constructs were then generated for tetracycline-regu-
lated expression as for TRPC5 HEK 293 Tet cells (46).
Intracellular Ca2measurement
Cells were seeded at 90% confluence into 96-well clear-bot-
tomed poly-D-lysine-coated black plates (Corning Life Sci-
ences) for HEK 293 cells and clear-bottomed Nunc plates
(Thermo Scientific) for A498 cells, Hs578T cells, and HUVECs
24 h before experimentation. Fura-2 Ca2 indicator dye was
used to monitor changes in intracellular ionized Ca2 concen-
tration. To perform the experiment, the cells were incubated
for 1 hwith fura-2-AM(2M) in standard bath solution (SBS) at
37 °C in the presence of 0.01% pluronic acid. SBS contained 135
mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 1.5 mM CaCl2, 8 mM glu-
cose, and 10 mM Hepes (pH titrated to 7.4 using NaOH). Sub-
sequently, the cells were washed twice with SBS before adding
C31 or ML204 for 30 min before making Ca2measurements.
The fura-2 fluorescence was recorded using a 96-well fluores-
cence plate reader and the excitation wavelengths of 340 and
380 nm (FlexStation II384, Molecular Devices, Sunnyvale, CA).
For TRPV4 recordings, fluo-4/AM was used in place of fura-2/
AM, and 2.5 mM probenecid was included to inhibit leak of
fluo-4. Fluo-4 was excited at 485 nm, and emitted light was
collected at 525 nm. Ca2 was indicated by the ratio of the
fluorescence (F) emission intensities for the two excitation
wavelengths. Measurements were made at room temperature
(21 3 °C).
Patch-clamp recording
Conventional whole-cell configuration and outside-out
patch-clamp recordings were performed under voltage clamp
at room temperature using 2–4-megaohm patch pipettes fab-
ricated from borosilicate glass capillaries with an outside diam-
eter of 1 mm and an inside diameter of 0.58 mm (Harvard
Apparatus). The currents were recorded using an Axopatch
200B amplifier, digitized by a Digidata 1440, and recorded to
computer using pCLAMP10 (Molecular Devices). The data
were filtered at 1 kHz and analyzed off-line using Clampfit soft-
ware (version 10.2, Molecular Devices) and Origin software
version 9.1 (OriginLab, Northampton, MA). The bath solution
was SBS, and the pipette solution (intracellular solution) con-
tained 145 mM CsCl, 2 mM MgCl2, 10 mM Hepes, 1 mM EGTA
(free acid), 5 mM ATP (sodium salt), and 0.1 mM NaGTP
(sodium salt), titrated to pH 7.2 with CsOH. Cells were plated
24 h previously on glass coverslips at a low density of 20–30%
and induced with tetracycline (1 g/ml).
C31 synthesis
The compoundwas synthesized as described previously (28).
Chemicals and reagents
EA was prepared as described previously (8). C31 was stored
at 20 °C as a 10 mM stock. All commercial chemicals used in
this work were purchased from Sigma-Aldrich, except where
stated. RO2959 was from Aobious Inc. Fluo-4/AM was from
Life Technologies. For stocks, all chemicals were dissolved in
100% DMSO except S1P, which was dissolved in methanol at 5
mM and Gd3 (GdCl3) in deionized water at 100 mM.
Figure 14. Additional data for the effects of C31 and RO2959 on hista-
mine-evoked Ca2 entry into endothelial cells. A, example Ca2measure-
ment data from a 96-well plate showing effects of 100 nM C31 and 10 M
RO2959onCa2 elevation in response to 100Mhistamine in the continuous
presence of extracellular 1.5 mM Ca2 (N 6/data point). Summary data for
experiments of the same type (A)measuredat thepeak response (B) and300 s
(C) after the start of histamine application (n/N  3/18). D, summary Ca2
measurement data for the effects of 100 nM C31 and 10 M RO2959 on the
peak Ca2 elevation in response to 0.3 M histamine in the continuous pres-
ence of extracellular 1.5 mM Ca2 in HUVECs (n/N 6/36). Error bars, S.D. **,
p 0.01; NS, not significant.
Table 1
Summary of IC50 values in pM and ranked from lowest to highest
The channel type studied is indicated on the left. TRPC4, TRPC5, TRPC4-TRPC1,
and TRPC5-TRPC1, human channel constructs expressed in HEK 293 cells. Fura-2
(Ca2), FlexStation 96-well recordings. Patch, whole-cell voltage-clamp recordings
with current measured at the indicated voltage (in some cases, the current was
measured at 90 or 90 mV instead of 100 or 100 mV because the current
amplitude saturated the amplifier in a small number of these experiments).
Channel Assay Agonist C31 IC50
pM
TRPC4-TRPC1 Patch 100 mV 200 nM S1P 9
TRPC4-TRPC1 Fura-2 (Ca2) 200 nM S1P 11
TRPC4 Patch 100 mV 200 nM S1P 12
TRPC4 Patch 100 mV 200 nM S1P 30
TRPC4-TRPC1 Fura-2 (Ca2) 10 nM EA 33
TRPC4-TRPC1 Patch 90 mV 10 nM EA 42
A498 endogenous Fura-2 (Ca2) 100 nM EA 48
TRPC4-TRPC1 Patch 100 mV 200 nM S1P 59
TRPC4-TRPC1 Patch 90 mV 30 nM EA 61
TRPC4 Patch 90 mV 10 nM EA 63
TRPC4-TRPC1 Patch 90 mV 10 nM EA 68
TRPC4-TRPC1 Patch 90 mV 30 nM EA 78
Hs578T endogenous Fura-2 (Ca2) 100 nM EA 110
TRPC4 Patch 90 mV 10 nM EA 169
TRPC5-TRPC1 Fura-2 (Ca2) 10 nM EA 199
TRPC4 Fura-2 (Ca2) 10 nM EA 349
TRPC4-TRPC1 Patch 90 mV 100 nM EA 441
TRPC4-TRPC1 Patch 90 mV 100 nM EA 481
TRPC4 Patch 90 mV 100 nM EA 593
TRPC4 Patch 90 mV 100 nM EA 916
TRPC5 Fura-2 (Ca2) 10 nM EA 1300
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Data analysis
Origin software was used to analyze and present the results.
Concentration-response curves were fitted using the Hill equa-
tion. The data points are shown using scatter plots, and S.D.
values are represented as error bars. The number of indepen-
dent experiments is indicated by n, and the number of repli-
cates within an independent experiment is indicated as N (e.g.
wells in a 96-well plate). Tests of significance were performed
using a paired two-sample t test, and statistical significance is
indicated by an asterisk (*, p 0.05; **, p 0.01; ***, p 0.001).
Author contributions—H. N. R. performed the calcium measure-
ment studies that initially identified the potency of the inhibitor,
contributed intellectually, analyzed data, generated figures, and
wrote parts of the manuscript. M. J. L., K. E. M., and N. M. B. gener-
ated the concatemers and stable cell lines. K. Muraki contributed
intellectually, generated figures, analyzed data, and performed the
patch-clamp experiments supported by H. N. R., S. Y. C., and Y. T.,
andM. H., N. H., R. T., R. F., R. S. B., andM. C. performed or advised
on chemical synthesis and usage. H. J. G. and K. Miteva performed
histamine and HUVEC cell experiments. H. L. A., M. A. B., L. M.,
H. W., and P. N. provided intellectual input or technical advice. All
authors commented on the manuscript. D. J. B. initiated the project,
generated research funds and ideas, led and coordinated the project,
interpreted data, and wrote most of the paper.
References
1. Abramowitz, J., and Birnbaumer, L. (2009) Physiology and pathophysiol-
ogy of canonical transient receptor potential channels. FASEB J. 23,
297–328
2. Beech, D. J. (2013) Characteristics of transient receptor potential canoni-
cal calcium-permeable channels and their relevance to vascular physiol-
ogy and disease. Circ. J. 77, 570–579
3. Wes, P. D., Chevesich, J., Jeromin, A., Rosenberg, C., Stetten, G., and
Montell, C. (1995) TRPC1, a human homolog of aDrosophila store-oper-
ated channel. Proc. Natl. Acad. Sci. U.S.A. 92, 9652–9656
4. Xu, S. Z., Muraki, K., Zeng, F., Li, J., Sukumar, P., Shah, S., Dedman, A.M.,
Flemming, P. K., McHugh, D., Naylor, J., Cheong, A., Bateson, A. N.,
Munsch, C. M., Porter, K. E., and Beech, D. J. (2006) A sphingosine-1-
phosphate-activated calcium channel controlling vascular smoothmuscle
cell motility. Circ. Res. 98, 1381–1389
5. Xu, S. Z., Sukumar, P., Zeng, F., Li, J., Jairaman, A., English, A., Naylor, J.,
Ciurtin, C., Majeed, Y., Milligan, C. J., Bahnasi, Y. M., Al-Shawaf, E., Por-
ter, K. E., Jiang, L. H., Emery, P., et al. (2008) TRPC channel activation by
extracellular thioredoxin. Nature 451, 69–72
6. Storch,U., Forst, A. L., Philipp,M.,Gudermann, T., andMederos y Schnit-
zler, M. (2012) Transient receptor potential channel 1 (TRPC1) reduces
calcium permeability in heteromeric channel complexes. J. Biol. Chem.
287, 3530–3540
7. Stru¨bing, C., Krapivinsky, G., Krapivinsky, L., and Clapham, D. E. (2001)
TRPC1 and TRPC5 form a novel cation channel in mammalian brain.
Neuron 29, 645–655
8. Akbulut, Y., Gaunt, H. J.,Muraki, K., Ludlow,M. J., Amer,M. S., Bruns, A.,
Vasudev,N. S., Radtke, L.,Willot,M.,Hahn, S., Seitz, T., Ziegler, S., Christ-
mann, M., Beech, D. J., and Waldmann, H. (2015) ()-Englerin A is a
potent and selective activator of TRPC4 and TRPC5 calcium channels.
Angew. Chem. Int. Ed. Engl. 54, 3787–3791
9. Prakriya, M., and Lewis, R. S. (2015) Store-operated calcium channels.
Physiol. Rev. 95, 1383–1436
10. Bon, R. S., and Beech, D. J. (2013) In pursuit of small molecule chemistry
for calcium-permeable non-selective TRPC channels: mirage or pot of
gold? Br. J. Pharmacol. 170, 459–474
11. Carson, C., Raman, P., Tullai, J., Xu, L., Henault, M., Thomas, E., Yeola, S.,
Lao, J., McPate,M., Verkuyl, J. M.,Marsh, G., Sarber, J., Amaral, A., Bailey,
S., Lubicka, D., et al. (2015) Englerin A agonizes the TRPC4/C5 cation
channels to inhibit tumor cell line proliferation. PLoS One 10, e0127498
12. Ludlow,M. J., Gaunt, H. J., Rubaiy, H.N.,Musialowski, K. E., Blythe,N.M.,
Vasudev, N. S., Muraki, K., and Beech, D. J. (2017) ()-Englerin A-evoked
cytotoxicity is mediated by Na influx and counteracted by Na/K-
ATPase. J. Biol. Chem. 292, 723–731
13. Miller, M., Shi, J., Zhu, Y., Kustov, M., Tian, J. B., Stevens, A., Wu, M., Xu,
J., Long, S., Yang, P., Zholos, A. V., Salovich, J. M.,Weaver, C. D., Hopkins,
C. R., Lindsley, C.W., et al. (2011) Identification ofML204, a novel potent
antagonist that selectively modulates native TRPC4/C5 ion channels.
J. Biol. Chem. 286, 33436–33446
14. Zheng, F., and Phelan, K. D. (2014) The role of canonical transient recep-
tor potential channels in seizure and excitotoxicity. Cells 3, 288–303
15. Phelan, K. D., Shwe, U. T., Abramowitz, J., Wu, H., Rhee, S. W., Howell,
M. D., Gottschall, P. E., Freichel, M., Flockerzi, V., Birnbaumer, L., and
Zheng, F. (2013) Canonical transient receptor channel 5 (TRPC5) and
TRPC1/4 contribute to seizure and excitotoxicity by distinct cellular
mechanisms.Mol. Pharmacol. 83, 429–438
16. Riccio, A., Li, Y., Moon, J., Kim, K. S., Smith, K. S., Rudolph, U., Gapon, S.,
Yao, G. L., Tsvetkov, E., Rodig, S. J., Van’t Veer, A.,Meloni, E. G., Carlezon,
W. A., Jr., Bolshakov, V. Y., and Clapham, D. E. (2009) Essential role for
TRPC5 in amygdala function and fear-related behavior.Cell 137, 761–772
17. Riccio, A., Li, Y., Tsvetkov, E., Gapon, S., Yao, G. L., Smith, K. S., Engin, E.,
Rudolph, U., Bolshakov, V. Y., and Clapham, D. E. (2014) Decreased anx-
iety-like behavior and Gq/11-dependent responses in the amygdala of
mice lacking TRPC4 channels. J. Neurosci. 34, 3653–3667
18. Westlund, K. N., Zhang, L. P., Ma, F., Nesemeier, R., Ruiz, J. C., Ostertag,
E. M., Crawford, J. S., Babinski, K., andMarcinkiewicz, M.M. (2014) A rat
knockout model implicates TRPC4 in visceral pain sensation. Neurosci-
ence 262, 165–175
19. Wei, Z. L., Nguyen, M. T., O’Mahony, D. J., Acevedo, A., Zipfel, S., Zhang,
Q., Liu, L., Dourado, M., Chi, C., Yip, V., DeFalco, J., Gustafson, A., Emer-
ling, D. E., Kelly, M. G., Kincaid, J., et al. (2015) Identification of orally-
bioavailable antagonists of the TRPV4 ion-channel. Bioorg. Med. Chem.
Lett. 25, 4011–4015
20. Camacho London˜o, J. E., Tian, Q., Hammer, K., Schro¨der, L., Camacho
London˜o, J., Reil, J. C., He, T., Oberhofer, M., Mannebach, S., Mathar, I.,
Philipp, S. E., Tabellion, W., Schweda, F., Dietrich, A., Kaestner, L., et al.
(2015) A background Ca2 entry pathway mediated by TRPC1/TRPC4 is
critical for development of pathological cardiac remodelling. Eur. Heart J.
36, 2257–2266
21. Alawi, K. M., Russell, F. A., Aubdool, A. A., Srivastava, S., Riffo-Vasquez,
Y., Baldissera, L., Jr., Thakore, P., Saleque, N., Fernandes, E. S., Walsh,
D. A., and Brain, S. D. (2017) Transient receptor potential canonical 5
(TRPC5) protects against pain and vascular inflammation in arthritis and
joint inflammation. Ann. Rheum. Dis. 76, 252–260
22. Sukumar, P., Sedo, A., Li, J., Wilson, L. A., O’Regan, D., Lippiat, J. D.,
Porter, K. E., Kearney, M. T., Ainscough, J. F., and Beech, D. J. (2012)
Constitutively active TRPC channels of adipocytes confer a mechanism
for sensing dietary fatty acids and regulating adiponectin. Circ. Res. 111,
191–200
23. Schaldecker, T., Kim, S., Tarabanis, C., Tian, D., Hakroush, S., Caston-
guay, P., Ahn,W.,Wallentin, H., Heid, H., Hopkins, C. R., Lindsley, C.W.,
Riccio, A., Buvall, L., Weins, A., and Greka, A. (2013) Inhibition of the
TRPC5 ion channel protects the kidney filter. J. Clin. Invest. 123,
5298–5309
24. Lau, O. C., Shen, B., Wong, C. O., Tjong, Y. W., Lo, C. Y., Wang, H. C.,
Huang, Y., Yung, W. H., Chen, Y. C., Fung, M. L., Rudd, J. A., and Yao, X.
(2016) TRPC5 channels participate in pressure-sensing in aortic barore-
ceptors. Nat. Commun. 7, 11947
25. Wei, H., Sagalajev, B., Yu¨zer, M. A., Koivisto, A., and Pertovaara, A. (2015)
Regulation of neuropathic pain behavior by amygdaloid TRPC4/C5 chan-
nels. Neurosci. Lett. 608, 12–17
26. Kumar, B., Dreja, K., Shah, S. S., Cheong, A., Xu, S. Z., Sukumar, P., Naylor,
J., Forte, A., Cipollaro, M., McHugh, D., Kingston, P. A., Heagerty, A. M.,
Munsch, C.M., Bergdahl, A., Hultgårdh-Nilsson, A., et al. (2006) Upregu-
TRPC1/4/5 inhibitor
8172 J. Biol. Chem. (2017) 292(20) 8158–8173
 at U
N
IV
ERSITY
 O
F LEED
S on June 26, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
lated TRPC1 channel in vascular injury in vivo and its role in human
neointimal hyperplasia. Circ. Res. 98, 557–563
27. Gaunt, H. J., Vasudev, N. S., and Beech, D. J. (2016) Transient receptor
potential canonical 4 and 5 proteins as targets in cancer therapeutics. Eur.
Biophys. J. 45, 611–620
28. Chenard, B., and Gallaschun, R. (September 18, 2014) Substituted xanthines
andmethods of use thereof. International PatentWO2014143799 A2
29. AL-Shawaf, E., Tumova, S., Naylor, J., Majeed, Y., Li, J., and Beech, D. J.
(2011) GVI phospholipase A2 role in the stimulatory effect of sphingo-
sine-1-phosphate on TRPC5 cationic channels.Cell Calcium 50, 343–350
30. Jung, S., Mu¨hle, A., Schaefer, M., Strotmann, R., Schultz, G., and Plant,
T. D. (2003) Lanthanides potentiate TRPC5 currents by an action at ex-
tracellular sites close to the pore mouth. J. Biol. Chem. 278, 3562–3571
31. Sukumar, P., and Beech, D. J. (2010) Stimulation of TRPC5 cationic chan-
nels by low micromolar concentrations of lead ions Pb2. Biochem. Bio-
phys. Res. Commun. 393, 50–54
32. Hofmann, T., Obukhov, A. G., Schaefer, M., Harteneck, C., Gudermann,
T., and Schultz, G. (1999) Direct activation of human TRPC6 and TRPC3
channels by diacylglycerol. Nature 397, 259–263
33. McHugh,D., Flemming, R., Xu, S. Z., Perraud, A. L., andBeech,D. J. (2003)
Critical intracellular Ca2 dependence of transient receptor potential
melastatin 2 (TRPM2) cation channel activation. J. Biol. Chem. 278,
11002–11006
34. Jairaman, A., and Prakriya, M. (2013) Molecular pharmacology of store-
operated CRAC channels. Channels 7, 402–414
35. Richter, J. M., Schaefer, M., and Hill, K. (2014) Clemizole hydrochloride is
a novel and potent inhibitor of transient receptor potential channel
TRPC5.Mol. Pharmacol. 86, 514–521
36. Zhu, Y., Lu, Y., Qu, C., Miller, M., Tian, J., Thakur, D. P., Zhu, J., Deng, Z.,
Hu, X., Wu, M., McManus, O. B., Li, M., Hong, X., Zhu, M. X., and Luo,
H. R. (2015) Identification and optimization of 2-aminobenzimidazole
derivatives as novel inhibitors of TRPC4 and TRPC5 channels. Br. J. Phar-
macol. 172, 3495–3509
37. Naylor, J., Minard, A., Gaunt, H. J., Amer, M. S., Wilson, L. A., Migliore,
M., Cheung, S. Y., Rubaiy, H.N., Blythe,N.M.,Musialowski, K. E., Ludlow,
M. J., Evans,W.D., Green, B. L., Yang, H., You, Y., et al. (2016)Natural and
synthetic flavonoidmodulation of TRPC5 channels.Br. J. Pharmacol. 173,
562–574
38. Majeed, Y., Bahnasi, Y., Seymour, V. A., Wilson, L. A., Milligan, C. J.,
Agarwal, A. K., Sukumar, P., Naylor, J., and Beech, D. J. (2011) Rapid and
contrasting effects of rosiglitazone on transient receptor potential TRPM3
and TRPC5 channels.Mol. Pharmacol. 79, 1023–1030
39. Richter, J. M., Schaefer, M., and Hill, K. (2014) Riluzole activates TRPC5
channels independently of plc activity. Br. J. Pharmacol. 171, 158–170
40. Philipp, S., Hambrecht, J., Braslavski, L., Schroth, G., Freichel, M., Mu-
rakami, M., Cavalie´, A., and Flockerzi, V. (1998) A novel capacitative cal-
cium entry channel expressed in excitable cells. EMBO J. 17, 4274–4282
41. Freichel, M., Suh, S. H., Pfeifer, A., Schweig, U., Trost, C., Weissgerber, P.,
Biel, M., Philipp, S., Freise, D., Droogmans, G., Hofmann, F., Flockerzi, V.,
and Nilius, B. (2001) Lack of an endothelial store-operated Ca2 current
impairs agonist-dependent vasorelaxation in TRP4/ mice. Nat. Cell
Biol. 3, 121–127
42. Xu, S. Z., and Beech, D. J. (2001) TRPC1 is a membrane-spanning subunit
of store-operated Ca2 channels in native vascular smooth muscle cells.
Circ. Res. 88, 84–87
43. Feske, S., Gwack, Y., Prakriya, M., Srikanth, S., Puppel, S. H., Tanasa, B.,
Hogan, P. G., Lewis, R. S., Daly,M., andRao, A. (2006)Amutation inOrai1
causes immune deficiency by abrogating CRAC channel function.Nature
441, 179–185
44. Yuan, J. P., Zeng, W., Huang, G. N., Worley, P. F., and Muallem, S. (2007)
STIM1heteromultimerizes TRPC channels to determine their function as
store-operated channels. Nat. Cell Biol. 9, 636–645
45. Cheng, K. T., Liu, X., Ong, H. L., Swaim, W., and Ambudkar, I. S. (2011)
Local Ca2 entry via Orai1 regulates plasma membrane recruitment of
TRPC1 and controls cytosolic Ca2 signals required for specific cell func-
tions. PLoS Biol. 9, e1001025
46. Zeng, F., Xu, S. Z., Jackson, P. K., McHugh, D., Kumar, B., Fountain, S. J.,
and Beech, D. J. (2004) Human TRPC5 channel activated by a multiplicity
of signals in a single cell. J. Physiol. 559, 739–750
TRPC1/4/5 inhibitor
J. Biol. Chem. (2017) 292(20) 8158–8173 8173
 at U
N
IV
ERSITY
 O
F LEED
S on June 26, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Christmann, Robin S. Bon, Katsuhiko Muraki and David J. Beech
Roger Taylor, Richard Foster, Herbert Waldmann, Peter Nussbaumer, Mathias 
Musialowski, Nicola M. Blythe, Hollie L. Appleby, Marc A. Bailey, Lynn McKeown,
Miteva, Sin Ying Cheung, Yasuyuki Tanahashi, Nurasyikin Hamzah, Katie E. 
Hussein N. Rubaiy, Melanie J. Ludlow, Matthias Henrot, Hannah J. Gaunt, Katarina
channels
Picomolar, selective, and subtype-specific small-molecule inhibition of TRPC1/4/5
doi: 10.1074/jbc.M116.773556 originally published online March 21, 2017
2017, 292:8158-8173.J. Biol. Chem. 
  
 10.1074/jbc.M116.773556Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
Supplemental material:
  
 http://www.jbc.org/content/suppl/2017/03/21/M116.773556.DC1
  
 http://www.jbc.org/content/292/20/8158.full.html#ref-list-1
This article cites 45 references, 19 of which can be accessed free at
 at U
N
IV
ERSITY
 O
F LEED
S on June 26, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
